Colorectal Cancer Drugs Market Size and Forecast 2024-2033|Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG

The Colorectal Cancer Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Colorectal Cancer Drugs Market:

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

According to The Business Research Company’s Colorectal Cancer Drugs Global Market Report 2024, The colorectal cancer drugs market size has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $20.74 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to integration of multimodal approaches, introduction of chemotherapy, advancements in surgical techniques, emergence of targeted therapies, clinical trials and research.

The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $26.39 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rise in personalized treatment, patient-centric care models, expansion of targeted therapies, adoption of combination therapies, regulatory acceleration. Major trends in the forecast period include immunotherapy advancements, precision medicine evolution, combination therapies, biomarker research and use, clinical trials innovation.

The increasing demand for personalized medicines is expected tom propel the growth of the colorectal cancer drugs market going forward. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that takes into account individual variations in patients’ genes, environments, and lifestyles. Personalized medicine is transforming the approach to CRC treatment, offering more individualized and effective care for patients. It is likely to continue driving the growth of the CRC drug market as research and drug development efforts become more tailored to specific genetic and molecular profiles. For instance, in October 2022, according to reports published by STAT, a US-based health-oriented news company, there were more than 75,000 genetic testing products and 300 personalized medicines. Therefore, the increasing demand for personalized medicine is driving the growth of the colorectal cancer drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=2590&type=smp

The colorectal cancer drugs market covered in this report is segmented –

1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators

2) By Class: Immunotherapy, Chemotherapy, Other Classes

3) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels

Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy. Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies.

The colorectal cancer drugs market report table of contents includes:

1. Executive Summary

2. Colorectal Cancer Drugs Market Characteristics

3. Colorectal Cancer Drugs Market Trends And Strategies

4. Colorectal Cancer Drugs Market – Macro Economic Scenario

5. Global Colorectal Cancer Drugs Market Size and Growth

26. South America Colorectal Cancer Drugs Market

27. Brazil Colorectal Cancer Drugs Market

28. Middle East Colorectal Cancer Drugs Market

29. Africa Colorectal Cancer Drugs Market

30. Colorectal Cancer Drugs Market Competitive Landscape And Company Profiles

Top Major Players: